Icilin inhibits E2F1-mediated cell cycle regulatory programs in prostate cancer

Biochem Biophys Res Commun. 2013 Nov 29;441(4):1005-10. doi: 10.1016/j.bbrc.2013.11.015. Epub 2013 Nov 12.

Abstract

Aberrant expression of cell cycle regulators have been implicated in prostate cancer development and progression. Therefore, understanding transcriptional networks controlling the cell cycle remain a challenge in the development of prostate cancer treatment. In this study, we found that icilin, a super-cooling agent, down-regulated the expression of cell cycle signature genes and caused G1 arrest in PC-3 prostate cancer cells. With reverse-engineering and an unbiased interrogation of a prostate cancer-specific regulatory network, master regulator analysis discovered that icilin affected cell cycle-related transcriptional modules and identified E2F1 transcription factor as a target master regulator of icilin. Experimental analyses confirmed that icilin reduced the activity and expression levels of E2F1. These results demonstrated that icilin inactivates a small regulatory module controlling the cell cycle in prostate cancer cells. Our study might provide insight into the development of cell cycle-targeted cancer therapeutics.

Keywords: Bioinformatics; Gene expression profiling; Icilin; Microarray; Prostate cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Cycle / drug effects
  • Cell Cycle / genetics
  • Cell Line, Tumor
  • DNA, Superhelical / drug effects*
  • E2F1 Transcription Factor / antagonists & inhibitors*
  • Humans
  • Male
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology*
  • Pyrimidinones / pharmacology*

Substances

  • DNA, Superhelical
  • E2F1 Transcription Factor
  • Pyrimidinones
  • icilin